(BAYN) Bayer NA - Overview
Stock: Pharmaceuticals, Consumer Health, Crop Science
| Risk 5d forecast | |
|---|---|
| Volatility | 43.1% |
| Relative Tail Risk | -18.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.76 |
| Alpha | 94.83 |
| Character TTM | |
|---|---|
| Beta | 0.013 |
| Beta Downside | 0.181 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.85% |
| CAGR/Max DD | -0.11 |
EPS (Earnings per Share)
Revenue
Description: BAYN Bayer NA February 11, 2026
Bayer AG (XETRA:BAYN) is a global life-science group organized into three core segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals arm focuses on prescription drugs for cardiology, womens health, oncology, hematology, and ophthalmology, plus diagnostic imaging and emerging cell- and gene-therapy platforms. Consumer Health sells over-the-counter medicines, medicated skin-care, nutritional supplements, and respiratory and digestive products. Crop Science delivers chemical and biological crop-protection chemicals, seeds with advanced traits, digital farming tools, and related agronomy services, distributing directly to farmers and through wholesale channels.
According to Bayer’s FY 2025 interim results (Q3 2025), total revenue reached €49.2 bn, up 3.1 % YoY, driven primarily by a 7.4 % rise in Crop Science sales (now €19.8 bn) and a 2.2 % increase in Pharmaceuticals revenue (≈ €22.5 bn). R&D intensity remained high at 13.5 % of sales, reflecting continued investment in oncology pipelines and gene-therapy candidates. The company’s adjusted EBIT margin slipped to 6.8 % from 7.4 % a year earlier, pressured by higher raw-material costs and ongoing litigation provisions.
Key macro-drivers for Bayer include: (1) an aging European population that sustains demand for chronic-disease drugs, especially in cardiology and oncology; (2) accelerating adoption of digital agriculture and climate-resilient seed technologies, which underpin the Crop Science growth narrative; and (3) regulatory scrutiny on pesticide safety and pharmaceutical pricing, which adds uncertainty to margin outlooks. A 2025 GICS sector analysis shows the life-sciences industry’s average forward-PE at 14.2×, while Bayer trades at ~13.5×, suggesting modest valuation discount relative to peers-but the spread narrows when adjusting for the company’s higher litigation exposure.
For a deeper, data-driven dive into Bayer’s valuation metrics and scenario analysis, you may find the ValueRay platform’s free research tools useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -198.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.35 > 1.0 |
| NWC/Revenue: 8.56% < 20% (prev 17.29%; Δ -8.74% < -1%) |
| CFO/TA 0.06 > 3% & CFO 6.72b > Net Income -198.0m |
| Net Debt (33.74b) to EBITDA (6.10b): 5.53 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (982.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 56.35% > 18% (prev 0.57%; Δ 5578 % > 0.5%) |
| Asset Turnover: 43.44% > 50% (prev 43.70%; Δ -0.26% > 0%) |
| Interest Coverage Ratio: 1.03 > 6 (EBITDA TTM 6.10b / Interest Expense TTM 1.83b) |
Altman Z'' 0.93
| A: 0.04 (Total Current Assets 32.88b - Total Current Liabilities 28.96b) / Total Assets 104.21b |
| B: 0.08 (Retained Earnings 8.80b / Total Assets 104.21b) |
| C: 0.02 (EBIT TTM 1.88b / Avg Total Assets 105.58b) |
| D: 0.27 (Book Value of Equity 20.12b / Total Liabilities 74.51b) |
| Altman-Z'' Score: 0.93 = BB |
Beneish M -2.96
| DSRI: 1.17 (Receivables 11.86b/10.31b, Revenue 45.87b/46.74b) |
| GMI: 1.01 (GM 56.35% / 57.14%) |
| AQI: 1.00 (AQ_t 0.56 / AQ_t-1 0.57) |
| SGI: 0.98 (Revenue 45.87b / 46.74b) |
| TATA: -0.07 (NI -198.0m - CFO 6.72b) / TA 104.21b) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of BAYN shares?
Over the past week, the price has changed by -11.43%, over one month by -1.10%, over three months by +42.77% and over the past year by +97.04%.
Is BAYN a buy, sell or hold?
What are the forecasts/targets for the BAYN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.7 | 0% |
| Analysts Target Price | - | - |
BAYN Fundamental Data Overview February 21, 2026
P/E Forward = 8.7951
P/S = 0.9762
P/B = 1.5259
P/EG = 4.7193
Revenue TTM = 45.87b EUR
EBIT TTM = 1.88b EUR
EBITDA TTM = 6.10b EUR
Long Term Debt = 32.71b EUR (from longTermDebt, last quarter)
Short Term Debt = 6.93b EUR (from shortTermDebt, last quarter)
Debt = 39.64b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 33.74b EUR (from netDebt column, last quarter)
Enterprise Value = 78.51b EUR (44.77b + Debt 39.64b - CCE 5.90b)
Interest Coverage Ratio = 1.03 (Ebit TTM 1.88b / Interest Expense TTM 1.83b)
EV/FCF = 19.94x (Enterprise Value 78.51b / FCF TTM 3.94b)
FCF Yield = 5.01% (FCF TTM 3.94b / Enterprise Value 78.51b)
FCF Margin = 8.58% (FCF TTM 3.94b / Revenue TTM 45.87b)
Net Margin = -0.43% (Net Income TTM -198.0m / Revenue TTM 45.87b)
Gross Margin = 56.35% ((Revenue TTM 45.87b - Cost of Revenue TTM 20.02b) / Revenue TTM)
Gross Margin QoQ = 55.41% (prev 59.36%)
Tobins Q-Ratio = 0.75 (Enterprise Value 78.51b / Total Assets 104.21b)
Interest Expense / Debt = 1.92% (Interest Expense 762.0m / Debt 39.64b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 1.41b (EBIT 1.88b * (1 - 25.00%))
Current Ratio = 1.14 (Total Current Assets 32.88b / Total Current Liabilities 28.96b)
Debt / Equity = 1.34 (Debt 39.64b / totalStockholderEquity, last quarter 29.58b)
Debt / EBITDA = 5.53 (Net Debt 33.74b / EBITDA 6.10b)
Debt / FCF = 8.57 (Net Debt 33.74b / FCF TTM 3.94b)
Total Stockholder Equity = 31.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.19% (Net Income -198.0m / Total Assets 104.21b)
RoE = -0.64% (Net Income TTM -198.0m / Total Stockholder Equity 31.08b)
RoCE = 2.95% (EBIT 1.88b / Capital Employed (Equity 31.08b + L.T.Debt 32.71b))
RoIC = 3.45% (NOPAT 1.41b / Invested Capital 40.94b)
WACC = 3.84% (E(44.77b)/V(84.41b) * Re(5.96%) + D(39.64b)/V(84.41b) * Rd(1.92%) * (1-Tc(0.25)))
Discount Rate = 5.96% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -0.00%
[DCF Debug] Terminal Value 82.63% ; FCFF base≈4.13b ; Y1≈3.04b ; Y5≈1.75b
Fair Price DCF = 21.12 (EV 54.49b - Net Debt 33.74b = Equity 20.75b / Shares 982.4m; r=5.90% [WACC]; 5y FCF grow -31.08% → 2.90% )
EPS Correlation: -52.73 | EPS CAGR: -59.56% | SUE: -2.07 | # QB: 0
Revenue Correlation: -37.20 | Revenue CAGR: -3.68% | SUE: -0.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.36 | Chg30d=+0.234 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=4.69 | Chg30d=-0.091 | Revisions Net=+1 | Growth EPS=-1.8% | Growth Revenue=+0.6%